Here, we show that engineering tumor-specific T cells to secrete IFNα9 prolonged survival over IFNα4, however this approach relies on constitutive IFNα secretion by the transferred T cells, most likely resulting in elevated levels of IFNα systemically. The gene discussed is IFNA2; the disease is neoplasm.